Your browser is no longer supported. Please, upgrade your browser.
Settings
ARIA ARIAD Pharmaceuticals, Inc. daily Stock Chart
ARIA [NASD]
ARIAD Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.18 Insider Own0.20% Shs Outstand194.36M Perf Week0.17%
Market Cap4.62B Forward P/E- EPS next Y-0.39 Insider Trans-39.13% Shs Float187.76M Perf Month95.63%
Income-31.60M PEG- EPS next Q-0.18 Inst Own87.80% Short Float16.95% Perf Quarter119.70%
Sales186.20M P/S24.79 EPS this Y-40.80% Inst Trans0.97% Short Ratio3.04 Perf Half Y197.62%
Book/sh-0.24 P/B- EPS next Y-875.00% ROA-5.40% Target Price20.63 Perf Year344.76%
Cash/sh1.62 P/C14.67 EPS next 5Y- ROE37.10% 52W Range4.37 - 23.81 Perf YTD90.92%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-62.90% 52W High-0.25% Beta2.06
Dividend %- Quick Ratio3.20 Sales past 5Y-7.90% Gross Margin98.30% 52W Low443.48% ATR0.67
Employees459 Current Ratio3.20 Sales Q/Q58.10% Oper. Margin-73.60% RSI (14)89.05 Volatility0.27% 2.26%
OptionableYes Debt/Eq- EPS Q/Q50.90% Profit Margin-17.00% Rel Volume1.11 Prev Close23.70
ShortableYes LT Debt/Eq- EarningsFeb 06 BMO Payout- Avg Volume10.48M Price23.75
Recom2.70 SMA2039.55% SMA5063.99% SMA200125.71% Volume11,638,351 Change0.21%
Jan-11-17Downgrade SunTrust Buy → Hold
Jan-10-17Upgrade Barclays Underweight → Equal Weight $9 → $24
Jan-10-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-10-17Downgrade Jefferies Buy → Hold
Nov-03-16Initiated Deutsche Bank Hold $9.50
Oct-25-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-24-16Downgrade JP Morgan Neutral → Underweight
Oct-05-16Initiated SunTrust Buy $22
Sep-26-16Initiated Leerink Partners Outperform $20
May-11-16Reiterated Barclays Underweight $6 → $8
Jan-19-16Initiated Barclays Underweight $6
May-08-15Reiterated UBS Neutral $7 → $9
Mar-25-14Resumed HC Wainwright Buy $14
Feb-26-14Upgrade Maxim Group Hold → Buy $11
Feb-26-14Downgrade Chardan Capital Markets Buy → Neutral
Jan-24-14Upgrade BMO Capital Markets Market Perform → Outperform $8 → $14
Jan-06-14Reiterated UBS Neutral $2.50 → $7.50
Dec-23-13Upgrade Chardan Capital Markets Neutral → Buy $9
Dec-20-13Reiterated BMO Capital Markets Market Perform $4 → $8
Dec-10-13Upgrade Stifel Hold → Buy $7
Jan-20-17 05:25PM  Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC
02:55PM  Ariad played hardball to boost Takeda buyout price, federal filings show at bizjournals.com
07:00AM  Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017
04:40AM  Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)?
Jan-19-17 03:00PM  Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc. Business Wire
Jan-18-17 04:41PM  5 Expensive Drugs That Could End Up in Trump's Crosshairs at Motley Fool
10:48AM  Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders PR Newswire
08:44AM  Jazz Begins Phase III Study for Label Expansion of Defitelio
08:22AM  Becton, Dickinson Commercially Launches Precise WTA Kits
Jan-17-17 08:58AM  These 3 Stocks Have Doubled Since Election Day at Motley Fool
Jan-13-17 08:22PM  Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)
05:18PM  ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited PR Newswire
08:21AM  These 3 Stocks Quadrupled in Just 1 Year at Motley Fool
08:00AM  ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
07:29AM  ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
Jan-12-17 08:00PM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
Jan-11-17 08:55AM  Ariad Pharm downgraded by SunTrust
07:10AM  Former Ariad CEO Berger says Takeda deal was 'merely a matter of time' at bizjournals.com
Jan-10-17 03:06PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
02:34PM  Ariad Pharmaceuticals Cash Acquisition by Takeda Pharmaceuticals Could a Second Buyer Surface Accesswire
01:13PM  Takeda deal results in a huge windfall for former Ariad CEO Harvey Berger at bizjournals.com
12:21PM  After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next at Motley Fool
09:45AM  [$$] Japan's Takeda Looks to More Acquisitions to Fuel Global Growth at The Wall Street Journal
09:27AM  4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
08:43AM  ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
08:00AM  Takeda Takes the Hard Road at Bloomberg
05:01AM  Takeda Pharmaceutical Company Limited -- Moody's reviews Takeda Pharmaceutical's ratings for downgrade at Moody's
02:10AM  Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
02:08AM  Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal
01:02AM  [$$] Drug Deal Is Bet Price Pressures Have Eased at The Wall Street Journal
Jan-09-17 09:32PM  [$$] Takeda to Buy Ariad for $4.7 Billion at The Wall Street Journal +72.85%
08:55PM  Takeda Buys Ariad For $5.2 Billion: A Good Deal? at Barrons.com
08:51PM  The Merger Frenzy Is On: Here's What to Expect from the Rest of 2017
08:31PM  Japan's Takeda expects annual sales of Ariad's lung cancer drug to exceed $1 bln
06:45PM  These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
06:21PM  Why Ariad Pharmaceuticals, VCA, and Exact Sciences Jumped Today at Motley Fool
05:41PM  So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
05:33PM  The Real Apple of the Dow's Eye -- ICYMI
05:05PM  Harwood Feffer LLP Announces Investigation of ARIAD Pharmaceuticals, Inc. PR Newswire
03:55PM  Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
01:23PM  [$$] Takeda/Ariad: rough diamond at Financial Times
12:58PM  Why Ariad Pharmaceuticals Stock Soared Today at Motley Fool
12:52PM  Takeda Pharmaceutical to buy Ariad in $4.7 billion cash deal
12:48PM  [$$] Japan's Takeda to buy Ariad of the US for $5bn at Financial Times
12:48PM  Facebook Makes Powerful Move Higher -- How to Trade It, Along With 6 Other Active Stocks
12:46PM  ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
12:38PM  Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal at TheStreet
12:34PM  [$$] Drug Deal Is Bet Price Pressures Have Eased at The Wall Street Journal
11:23AM  Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation
11:19AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of ARIAD Pharmaceuticals, Inc. to Takeda Pharmaceutical Co. Ltd. for $24 Per Share is Fair to Shareholders - ARIA Accesswire
11:16AM  Ariad Pharmaceuticals shares skyrocket more than 70 percent after it strikes deal with Takeda at CNBC
10:26AM  Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal
10:15AM  Takeda to Buy Cancer Drug Maker Ariad for $5.2B at Investopedia
10:01AM  AA Still Kicks Off Q4? It???s Yellow Pages Mentality
09:50AM  Mondays 4 Biggest Biopharma Movers
09:11AM  Takeda acquires Cambridge cancer drug firm Ariad for $5.2B at bizjournals.com
09:06AM  How Was Incytes Profitability in 3Q16?
08:47AM  Early movers: URBN, SCAI, UNH, MCD & more at CNBC
08:34AM  Takeda is buying Ariad Pharmaceuticals in a $5.2 billion deal
08:13AM  Takeda to acquire Ariad Pharma in all-cash deal valued at about $5.2 billion at MarketWatch
08:10AM  Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 bln deal
08:02AM  ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion Business Wire
08:00AM  Takeda to Acquire ARIAD Pharmaceuticals, Inc. Business Wire
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com
Jan-03-17 07:35AM  ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-30-16 01:00PM  This Billionaires Fund Returned 30% This Year; Here Are Some of His Top Stock Picks at Insider Monkey
09:27AM  ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
Dec-21-16 09:15AM  Today's Reports on Biotech Movers Ariad Pharmaceuticals and Amicus Therapeutics Accesswire
Dec-13-16 11:38AM  3 Tempting Stocks to Avoid at Motley Fool
Dec-10-16 02:03PM  3 Big Advances In Cancer Treatment In 2016 at Motley Fool
Dec-08-16 10:45AM  3 Growth Stocks That Could Double at Motley Fool
08:01AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-07-16 04:32PM  Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win -6.79%
04:07PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
04:06PM  Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High
02:46PM  Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally
11:13AM  Bernie Sanders' 'Trump Proposal' To Lower Drug Prices Blocked By Senate Republicans
10:00AM  ARIAD Presents Data on Brigatinib from the World Conference on Lung Cancer Call scheduled for 10:00 am ET today
07:35AM  ARIADs Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study Business Wire
Dec-06-16 07:35AM  ARIAD Announces Data Presentations at American Society of Hematology Meeting Business Wire
Dec-05-16 07:35AM  ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer Business Wire
Dec-02-16 05:41PM  Why Ariad Pharmaceuticals Soared 47% in November at Motley Fool
04:05PM  ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer Business Wire
Nov-30-16 04:06PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:45AM  Ariad Leukemia Drug Gets Full US Approval (ARIA) at Investopedia
10:03AM  ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
01:41AM  Hedge Funds Are Souring On Chicos FAS, Inc. (CHS) at Insider Monkey
Nov-29-16 07:35AM  ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial Business Wire
Nov-26-16 07:18AM  Hedge Funds Are Betting On Ariad Pharmaceuticals, Inc. (ARIA) at Insider Monkey
Nov-25-16 09:22AM  Bulls following momentum in Ariad
Nov-18-16 04:07PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:30AM  New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day
Nov-17-16 01:04PM  ARIAD PHARMACEUTICALS INC Financials +7.93%
08:56AM  3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
Nov-16-16 05:04PM  ARIAD Announces Data Presentations at the World Conference on Lung Cancer Business Wire
Nov-14-16 12:51PM  ETFs with exposure to ARIAD Pharmaceuticals, Inc. : November 14, 2016 +6.76%
07:35AM  ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month Business Wire
Nov-11-16 07:11AM  ARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARIA-US : November 11, 2016 +5.61%
Nov-10-16 10:22AM  ARIAD Pharmaceuticals, Inc. :ARIA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
08:31AM  Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Panayiotopoulos ParisPresident and CEOJan 13Option Exercise0.0066,6000192,678Jan 17 05:06 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityJan 09Option Exercise7.8232,000250,240161,404Jan 10 06:17 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityJan 09Sale23.7832,000760,960129,404Jan 10 06:17 PM
CLACKSON TIMOTHY PPresident, R&D, CSOOct 24Sale9.5619,638187,739197,884Oct 25 04:07 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityOct 03Sale13.4647,384637,812129,404Oct 05 04:17 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 28Sale13.988,750122,311217,522Sep 28 04:19 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 26Option Exercise0.0017,5000226,272Sep 28 04:19 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 26Option Exercise0.0010,0000176,788Sep 28 04:20 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 22Sale13.4320,000268,536208,772Sep 23 05:46 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 15Option Exercise7.8259,369464,266288,141Sep 16 05:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 15Sale11.7359,369696,398228,772Sep 16 05:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOAug 22Sale10.4719,436203,538228,772Aug 23 04:12 PM
CLACKSON TIMOTHY PPresident, R&D, CSOAug 12Option Exercise7.6925,000192,250273,208Aug 15 04:16 PM
CLACKSON TIMOTHY PPresident, R&D, CSOAug 12Sale10.5025,000262,500248,208Aug 15 04:16 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 22Sale8.1118,286148,230248,208Jul 25 04:39 PM
Panayiotopoulos ParisPresident and CEOJul 13Option Exercise0.0066,6000154,689Jul 14 04:23 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 01Option Exercise3.8861,422238,585297,916Jul 05 04:07 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 01Sale7.4861,422459,634266,494Jul 05 04:07 PM
Cole Hugh MSVP, Chief Business OfficerJun 28Sale7.056,01242,38529,916Jun 29 04:25 PM
Cole Hugh MSVP, Chief Business OfficerJun 27Option Exercise0.0019,166035,928Jun 29 04:25 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJun 22Sale7.2823,999174,638264,742Jun 23 04:11 PM
LAVIDAS ATHANESEDirectorJun 15Option Exercise6.5546,250302,788177,881Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 15Sale8.2446,250381,137131,631Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 14Option Exercise6.4420,000128,800151,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 14Option Exercise4.916,25030,688111,750Jun 14 06:13 PM
Radaelli MassimoDirectorJun 14Sale8.136,25050,834105,500Jun 14 06:13 PM
LAVIDAS ATHANESEDirectorJun 14Sale8.1420,000162,852131,631Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 13Option Exercise5.4910,00054,900141,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 13Option Exercise6.5779,731523,551185,231Jun 14 06:13 PM
Radaelli MassimoDirectorJun 13Sale8.2579,731657,821105,500Jun 14 06:13 PM
LAVIDAS ATHANESEDirectorJun 13Sale8.2110,00082,050131,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 10Option Exercise1.3522,58830,494128,088Jun 14 06:13 PM
Radaelli MassimoDirectorJun 10Sale8.3022,588187,480105,500Jun 14 06:13 PM
Panayiotopoulos ParisPresident and CEOMay 12Buy7.4126,990199,99688,089May 13 05:59 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMay 02Sale7.1311,70083,478306,503May 02 05:28 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityApr 29Option Exercise0.0017,3340172,422May 02 05:30 PM
Cantor Maria ESVP, Corporate AffairsApr 29Option Exercise0.0013,3340149,001May 02 05:32 PM
Haluska FrankSVP, Clinical R&D, CMOApr 29Option Exercise0.0017,3340164,345May 02 05:33 PM
Cole Hugh MSVP, Chief Business OfficerApr 29Option Exercise0.0017,334022,396May 02 05:29 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 29Option Exercise0.0023,4000318,203May 02 05:28 PM
Duvall Martin JEVP, CCOApr 29Option Exercise0.0018,0000111,039May 02 05:26 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 22Sale7.3721,409157,864294,803Apr 25 04:04 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 21Sale6.474,00025,871155,088Mar 22 04:02 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 21Sale6.472,37515,356262,115Mar 22 04:02 PM
Haluska FrankSVP, Clinical R&D, CMOMar 21Sale6.473,57523,116147,011Mar 22 04:01 PM
FITZGERALD EDWARD MExecutive VPMar 21Sale6.475,41735,037320,367Mar 22 04:01 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Option Exercise0.0010,8330345,463Mar 22 04:01 PM
Duvall Martin JEVP, CCOMar 19Option Exercise0.008,000097,039Mar 22 04:03 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 19Option Exercise0.008,0000159,088Mar 22 04:02 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 19Option Exercise0.004,7500264,490Mar 22 04:02 PM
Haluska FrankSVP, Clinical R&D, CMOMar 19Option Exercise0.006,5000150,586Mar 22 04:01 PM
FITZGERALD EDWARD MExecutive VPMar 19Option Exercise0.0010,8330325,784Mar 22 04:01 PM
Duvall Martin JEVP, CCOMar 19Sale6.474,00025,86793,039Mar 22 04:03 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Sale6.475,41735,039340,046Mar 22 04:01 PM
Cole Hugh MSVP, Chief Business OfficerMar 16Option Exercise6.217,50046,5757,500Mar 18 04:04 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 15Option Exercise1.303,7504,875154,838Mar 17 04:45 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 03Sale6.129,62558,866314,951Mar 03 08:12 PM
Duvall Martin JEVP, CCOMar 03Sale6.129,62558,86389,039Mar 03 08:07 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 03Sale6.129,62558,887259,740Mar 03 08:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 03Sale6.129,62558,867334,630Mar 03 08:00 PM
Cantor Maria ESVP, Corporate AffairsMar 03Sale6.129,62558,869132,742Mar 03 08:00 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 03Sale6.119,62558,852151,088Mar 03 07:59 PM
Haluska FrankSVP, Clinical R&D, CMOMar 03Sale6.1110,58864,733144,086Mar 03 07:58 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 02Sale6.0025,047150,282344,255Mar 03 08:00 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 01Option Exercise0.0019,2500324,576Mar 03 08:12 PM
Duvall Martin JEVP, CCOMar 01Option Exercise0.0019,250098,664Mar 03 08:07 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 01Option Exercise0.0019,2500269,365Mar 03 08:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 01Option Exercise0.0019,2500369,302Mar 03 08:00 PM
Cantor Maria ESVP, Corporate AffairsMar 01Option Exercise0.0019,2500142,367Mar 03 08:00 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 01Option Exercise0.0019,2500160,713Mar 03 07:59 PM
Haluska FrankSVP, Clinical R&D, CMOMar 01Option Exercise0.0019,2500154,674Mar 03 07:58 PM
DesRosier ThomasEVP, General CounselFeb 18Option Exercise0.0055,000055,000Mar 30 05:04 PM
Cantor Maria ESVP, Corporate AffairsFeb 01Option Exercise0.0029,3330139,250Feb 03 04:35 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 01Option Exercise0.0029,3330319,993Feb 03 04:37 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 01Option Exercise0.0029,3330151,557Feb 03 04:39 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 01Option Exercise0.0029,3330264,782Feb 03 04:38 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 01Option Exercise0.0029,3330156,130Feb 03 04:41 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 01Option Exercise0.0029,3330364,719Feb 03 04:43 PM
Duvall Martin JEVP, CCOFeb 01Option Exercise0.0029,333094,081Feb 03 04:46 PM
Panayiotopoulos ParisPresident and CEOFeb 01Buy4.9161,099299,99661,099Feb 03 05:43 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 01Sale4.8114,66770,517350,052Feb 03 04:43 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 01Sale4.8114,66770,548141,463Feb 03 04:41 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 01Sale4.8114,66770,515250,115Feb 03 04:38 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 01Sale4.8116,13377,587135,424Feb 03 04:39 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 01Sale4.8114,66770,515305,326Feb 03 04:37 PM
Cantor Maria ESVP, Corporate AffairsFeb 01Sale4.8216,13377,745123,117Feb 03 04:35 PM
Duvall Martin JEVP, CCOFeb 01Sale4.8114,66770,57879,414Feb 03 04:46 PM